Investors
Announcement 2021
Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability Emerging Markets Index for the fourth consecutive year
Newspaper Publication of Q2 FY 2021-22 Result
Glenmark Pharma reports revenue growth of 6.6% and PAT growth of 10.1% YoY for Q2 FY 2021-22
Glenmark's MDA Q2 FY 2021 - 22
Glenmark's Q2 FY 2021-22 Results
Q2 FY22 Earnings Call Invitation - November 15, 2021
Board Meeting Intimation - 12 November, 2021
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India
Glenmark launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler
Transcript of the 43rd AGM
Proceedings and Scrutinizer's Report of the 43rd AGM
Chairman's Speech at 43rd AGM
Glenmark receives marketing approval for Ryaltris®, an innovative combination nasal spray, in 13 countries across the EU and UK
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%
Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®) in 1000+ COVID-19 patients, findings reinforce the drug’s safety and efficacy in real world settings
43rd AGM Notice - Newspaper Advertisement
Glenmark AGM Notice 2021
Newspaper Publication of Q1 FY 2021-22 Result
Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22
Glenmark’s MDA Q1 FY 2021 – 22
Glenmark’s Q1 FY 2021-22 Results
Q1 FY22 Earnings Call Invitation – August 16, 2021
Board Meeting Intimation – 13th August, 2021
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets
Newspaper notice to shareholders for transfer of shares to IEPF
SCRIP_27 May 2021: Favipiravir Adds Near-Equivalent Of AZ India To Glenmark's Sales
Glenmark receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg
Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials
Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler
Glenmark releases interim data from PMS Study on Favipiravir
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
Newspaper Publication of Q4 FY 2020-21 Result
Glenmark’s consolidated revenues grow 2.8% to Rs. 1,09,439 Mn in FY21
Glenmark’s MDA Q4 FY 2020 – 21
Glenmark’s Q4 FY 2020-21 Results
Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe
Newspaper Advertisement for the Board Meeting on 28th May, 2021
Q4 FY21 Earnings Call Invitation – May 31, 2021
Board Meeting Intimation – 28th May, 2021
Glenmark launches Ryaltris®-AZ at an affordable price in India
Glenmark Pharmaceuticals Limited has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as Indo Health Services LLP)
Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
Proposed Initial Public Offering (“IPO”) of Glenmark Life Sciences Limited‐ Filing of draft red herring prospectus
Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity.
Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity
Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada
Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder
Glenmark receives ‘India Pharma Innovation of the Year’ Award from the Govt. of India
Glenmark’s Ryaltris®- innovative single nasal spray, ready to market in Russia
Newspaper Publication of Q3 FY 2020-21 Result
Glenmark launches SUTIB (Sunitinib) – priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58%
Glenmark’s Q3 FY 2020-21 Results
Glenmark’s consolidated sales rises by 3.88% to Rs. 27,605.07 Mn. in Q3 FY 2020-21
Glenmark’s MDA Q3 FY 2020 – 21
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1%
Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg
Newspaper Advertisement for the Board Meeting on 12th February, 2021
Board Meeting Intimation – 12th February, 2021
Q3 FY21 Earnings Call Invitation – February 15, 2021
Glenmark Pharmaceuticals receives ANDA approval for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg
About Us
Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future